3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
144
Neoplasm Metastasis
16
Neoplasms
8
Advanced Breast Cancer
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Doxorubicin
6
Trabectedin
5
pazopanib
4
Radiotherapy
4
ribociclib
3
pembrolizumab
3
palbociclib
3
Gemcitabine
3
brostallicin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Immunoglobulin G
2
Imatinib Mesylate
2
Ifosfamide
2
Docetaxel
2
Dexamethasone
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
tanespimycin
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
sitravatinib
1
saracatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled